North American Nuclear Medicine/Radiopharmaceuticals Market worth $2.98 Billion by 2020

North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

(EMAILWIRE.COM, September 04, 2019 ) The North American nuclear medicine market is expected to reach USD 2.98 Billion in 2020 from USD 1.97 Billion in 2015, growing at a CAGR of 8.6%. . Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat various diseases. The North American nuclear medicine market is segmented on the basis of types, applications, and countries.

Get PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=1108

The radiopharmaceuticals market, by type is broadly classified into two segments, namely, diagnostic and therapeutic radioisotopes. Radioisotopes in the diagnostic market are further categorized as SPECT and PET; while the therapeutic market is classified into beta emitters, brachytherapy isotopes, and alpha emitters. In 2015, the diagnostic segment is expected to account for the largest share of the North American nuclear medicine market, with the SPECT segment likely to account for the largest share of the diagnostic market. While, beta emitters is expected to account for the largest share of the therapeutic market in 2015.

The North American radiopharmaceuticals market, based on application is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into Cardiology, Lymphoma

In 2015, U.S. is poised to account for the largest share of the North American nuclear medicine market, followed by Canada. The U.S. market is slated to grow at the highest CAGR during the forecast period. The major factors driving market growth in U.S. include the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=1108